Saturday, December 12, 2020

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

 • Acquisition will add another key dimension to Boehringer Ingelheim’s focus on patients with difficult-to-treat solid tumors


• NBE-Therapeutics’ pipeline is based on its innovative next generation antibody-drug conjugate (ADC) technology platform


• NBE-Therapeutics’ will remain at its campus in Basel, Switzerland and operate as a new site within Boehringer Ingelheim’s R&D network


INGELHEIM, Germany & BASEL, Switzerland-Thursday 10 December 2020 [ AETOS Wire ]


(BUSINESS WIRE)-- Boehringer Ingelheim today announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC™ platform. NBE-Therapeutics’ lead compound NBE-002 is currently in phase I clinical studies for triple negative breast cancer and other solid tumors. Importantly, Boehringer Ingelheim gains access to an innovative and unique platform that it will use to build a leading ADC portfolio and develop potential combinations with other assets from its cancer immunology portfolio.


“NBE-Therapeutics’ iADC platform adds exceptional tumor targeting capabilities to our oncology portfolio. Together with our immune cell-targeting assets, this could enable new powerful combinations that will allow for efficacious and durable treatments for patients,” said Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit. “This acquisition is a further example of Boehringer Ingelheim’s long-term strategy to enhance our position as an innovator of novel cancer therapies for patients in need. We welcome NBE-Therapeutics’ richly talented team to Boehringer Ingelheim and we look forward to collaborating with them on this important work.”


The total transaction value is 1.18 billion euros and also includes contingent clinical and regulatory milestones.


“I am extremely proud of the NBE-Therapeutics’ team and delighted that our world class ADC expertise is being recognized by Boehringer Ingelheim. This transaction is a validation of our platform and its potential for the next generation cancer therapies,” said Bertrand Damour, Chief Executive Officer of NBE-Therapeutics. “We look forward to progressing NBE-002, our lead program and best-in-class anti ROR1 ADC, and to continuing the fight against cancer alongside Boehringer Ingelheim with its strong clinical development capabilities.”


Boehringer Ingelheim’s cancer cell directed research is focused on the development of targeted therapies for the treatment of difficult-to-treat solid tumors. Inducing tumor cell death is a key component, and ADC based approaches have emerged as a powerful targeted therapy with potential for induction of immunogenic cell death at reduced systemic exposure and toxicity.


The NBE-Therapeutics’ acquisition will significantly strengthen Boehringer Ingelheim’s strategic focus on targeted cancer cell-directed therapies and complements existing capabilities in antigen discovery as well as antibody and T-cell engager technologies. By combining its world-class, in-house research and development with that of highly innovative biotechnology companies, Boehringer Ingelheim is developing innovative therapies and accelerating the delivery of the next generation of cancer treatments. This builds on recent strategic acquisitions and collaborations, including the acquisition of ViraTherapeutics and AMAL Therapeutics, which are also contributing assets.


NBE-Therapeutics is headquartered in Basel, Switzerland, where it was founded with financial backing from a syndicate of both corporate and institutional investors, including the Boehringer Ingelheim Venture Fund, and PPF Group, as their largest shareholders, and Denmark’s Novo Holdings. NBE-Therapeutics’ technology platform and derived assets are protected by a broad portfolio of patents and licenses.


The consummation of the transaction is subject to customary closing conditions and is expected during the course of Q1 2021.


Please click on the following link for ‘Notes to Editors’:


http://www.boehringer-ingelheim.com/press-release/agreement-acquire-nbe-therapeutics


View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005538/en/


Contacts

NBE-Therapeutics

Bertrand Damour, CEO

E: bertrand.damour@NBE-Therapeutics.com


NBE-Therapeutics media enquiries:

Optimum Strategic Communications

Mary Clark, Manel Mateus, Elakiya Rangarajah

T: +44 (0) 20 3922 0900

E: NBE-Therapeutics@optimumcomms.com


Boehringer Ingelheim

Dr. Reinhard Malin

Head of Communications Innovation Unit

Boehringer Ingelheim Corporate Center GmbH

Media + PR

P: +49 6132 77-90815

press@boehringer-ingelheim.com


Linda Ruckel

Associate Director, Media and Corporate Reputation

Boehringer Ingelheim U.S.

Media + PR

P: + 203-791-6672

press@boehringer-ingelheim.com




Permalink : https://www.aetoswire.com/news/boehringer-ingelheim-to-acquire-nbe-therapeutics-for-eur-118-billion-significantly-enhancing-its-cancer-pipeline-portfolio-with-novel-antibody-drug-conjugates/en


No comments:

Post a Comment